Thermosensitive Pluronic® hydrogel: Prolonged injectable formulation for drug abuse

Drug Design, Development and Therapy

Volumn 4, Issue , 2010, Pages 255-262

  Derakhshandeh, Katayoun ^a   Fashi, Mahtab ^a   Seifoleslami, Seyedalireza ^b  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Forensic Medicine Organization   (Iran)

Author keywords

Kneading method; Naltrexone; Prolonged release; Thermosensitive hydrogel; Triacetyl cyclodextrin

Indexed keywords

BETA CYCLODEXTRIN; INORGANIC SALT; NALTREXONE; POLOXAMER; TRIACETYL BETA CYCLODEXTRIN; UNCLASSIFIED DRUG; BETA CYCLODEXTRIN DERIVATIVE; EXCIPIENT; NARCOTIC ANTAGONIST; TRIACETYL-BETA-CYCLODEXTRIN;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; HEAT SENSITIVITY; HYDROGEL; PH; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE FORMULATION; CHEMISTRY; DELAYED RELEASE FORMULATION; OPIATE ADDICTION; TEMPERATURE;

BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; DELAYED-ACTION PREPARATIONS; EXCIPIENTS; HYDROGELS; HYDROGEN-ION CONCENTRATION; INJECTIONS, SUBCUTANEOUS; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; POLOXAMER; TEMPERATURE;

EID: 79952065523     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S13289     Document Type: Article

References (36)

1. Heller J. Polymers for controlled parenteral delivery of peptides and proteins. Adv Drug Deliv Rev. 1993;10:163-204.
2. Langer R. New methods of drug delivery. Science. 1990;249: 1527-1533.
3. Reddy KR. Controlled release, pegylation, liposomal formulations: New mechanisms in the delivery of injectable drugs. Ann Pharmacother. 2000;34:915-922.
4. Hatefi A, Amsden B. Biodegradable injectable in situ forming drug delivery systems. J Control Rel. 2002;80:9-28.
5. Narasimhan B, Peppas NA. The physics of polymer dissolution: Modeling approaches and experimental behavior. Adv Polym Sci. 1997;128: 157-207.
6. Mallapragada SK, Peppas NA. Crystal unfolding and chain disentanglement during semicrystalline polymer dissolution. AlChE J. 1997; 43:870-876.
7. Yang L, Alexandridis P. Mass transport in ordered microstructures formed by block copolymers: Ramifications for controlled release applications. Polym Prep. 1999;40:349-350.
8. Harland RS, Gazzaniga A, Sangalli ME, Colombo P, Peppas NA. Drug/polymer matrix swelling and dissolution. Pharm Res. 1988;5: 488-492.
9. Mallapragada SK, Peppas NA. Crystal dissolution-controlled release systems: I. Physical characteristics and modeling analysis. J Control Rel. 1997;45:87-93.
10. Zhang L, Parsons DL, Navarre C, Kompella UB. Development and invitro evaluation of sustained release Poloxamer 407 gel formulations of ceftiofur. J Control Rel. 2002;85:73-81.
11. Escobar-Chávez JJ, López-Cervantes M, Naïk A, Kalia YN, Quintanar-Guerrero D, Ganem-Quintanar A. Applications of thermoreversible Pluronic F-127 gels in pharmaceutical formulations. J Pharm Pharmaceut Sci. 2006;9:339-358.
12. Desai SD, Blanchard J. Evaluation of Pluronic F-127 based sustainedrelease ocular delivery systems for pilocarpine using the albino rabbit eye model. J Pharm Sci. 1998;87:1190-1195.
13. Wenzel JG, Balaji KS, Koushik K, et al. Pluronic F127 gel formulations of deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle. J Control Rel. 2002;85:51-59.
14. Collet JH, Tait C, Attwood D. In vitro evaluation of poloxamer gels as controlled release systems using gamma scintigraphy. Proc Int Symp Contr Rel Bioact Mater. 1985;12:28-30.
15. Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC. Single and multiple-dose pharmacokinetics of longacting injectable naltrexone. Alcohol Clin Exp Res. 2006;30: 480-490.
16. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting ingectable naltrexone for alcohol dependence: A randomized controlled trial. JAMA. 2005;293:1617-1625.
17. Johnson BA. A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence. Expert Opin Pharmacother. 2006;7: 1065-1073.
18. Sullivan MA, Vosburg SK, Comer SD. Depot naltrexone: Antagonism of the reinforcing, subjective, and physiological effects of heroin. J Psychopharmacol. 2006;189:37-46.
19. Swainston Harrison T, Plosker GL, Keam SJ. Extended-release intramuscular naltrexone. Drugs. 2006;66:1741-1751.
20. O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR. Efficacy of extended-release naltrexone in alcohol dependent patients who are abstinent before treatment. J Clin Psychopharmacol. 2007;27: 507-512.
21. Pongpaibul Y, Maruyama K, Iwatsuru M. Formation and in-vitro evaluation of theophylline-loaded poly (methyl methacrylate) microspheres. J Pharm Pharmacol. 1988;40:530-533.
22. Hirayama F, Uekama K. Cyclodextrin-based controlled drug release system. Adv Drug Deliv Rev. 1999;36:125-141.
23. Fernandes CM, Veiga FJ. Effect of the hydrophobic nature of triacetyl- β-cyclodextrin on the complexation with nicardipine hydrochloride: Physicochemical and dissolution properties of the kneaded and spraydried complexes. Chem Pharm Bull. 2002;50:1597-1602.
24. Schmolka IR. Artificial skin I. Preparation and properties of Pluronic F-127 gels for treatment of burns. J Biomed Mater Res. 1972;6: 571-582.
25. Cohen S, Lobel E, Trevgada A, Peled Y. A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. J Control Rel. 1997;44:201-208.
26. Escobar-Chavez JJ, Lopez-Cervantes M, Naik A, Kalia YN, Quintanar-Guerrero D, Ganem-Quitanar A. applications of thermoreversible Pluronic F-127 gels in pharmaceutical formulations. J Pharm Pharm Sci. 2006;9:339-358.
27. Guzman M, Garsia FF, Molpeceres J, Aberturas MR. Polyoxyethylenepolyoxypropylene block copolymer gels as sustained release vehicles for subcutaneous drug administration. Int J Pharm. 1992;80:119-127.
28. Gilbert JC, Hadgraft J, Bye A, Brookes L. Drug release from Pluronic F127 gels. Int J Pharm. 1986;32:223-228.
29. Pandit N, Wang D. Salt effects on the diffusion and release rate of propranolol from poloxamer 407 gels. Int J Pharm. 1998;167: 183-189.
30. Moore T, Croy S, Mallapragada S, Pandit N. Experimental investigation and mathematical modeling of Pluronic F127 gel dissolution: Drug release in stirred systems. J Control Rel. 2000;67:191-202.
31. Narasimhan B, Langer R. Zero-order release of micro-and macromolecules from polymeric devices: The rule of the burst effect. J Control Rel. 1997;47:13-20.
32. Lemesle-Lamache V, Wouessidjewe D, Cheron M, Duchene D. Study of β-cyclodextrin and ethylated β-cyclodextrin salbutamol complexes, in vitro evaluation of sustained-release behavior of salbutamol. Int J Pharm. 1996;141:117-124.
33. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev. 1998;98:2045-2076.
34. Horiuchi Y, Hirayama F, Uekama K. Slow-release characteristics of diltiazem from ethylated -cyclodextrin complexes. J Pharm Sci. 1990;79:128-132.
35. Bibby DC, Davies NM, Tucker IG. Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. Int J Pharm. 2000;19:1-11.
36. Cabral-Marques HM, Hadgraft J, Kellaway IW. Int J Pharm. 1990;63: 259-266.